Pharmacokinetics and Comparative Bioavailability of Two Metformin Formulations after Single-Dose Administration in Healthy Subjects
Objective: To assess the average bioequivalence of two formulations of metformin after single-dose administration of each treatment to healthy subjects under fasting conditions by assessing the pharmacokinetic measures of systemic exposure and evaluating the confidence intervals (CIs) for each pharmacokinetic parameter.
Design: Randomised, comparative, single-dose, open-label, balanced, two-period, two-treatment, crossover study under fasting conditions. Participants: 20 healthy volunteers (ten men and ten women) took part in the study.
Methods: Subjects were investigated after a single dose of 850mg after a washout period of 7 days. Plasma samples were taken at regular time intervals according to the study protocol for measuring plasma metformin concentrations. Systemic exposure was estimated with the use of pharmacokinetic parameters (area under the curve of the plasma drug concentrations from time zero to the last sampling time [AUC0-36], area under the curve of the plasma drug concentrations from time zero to infinity [AUC0-∞], time to peak drug concentration [tmax], partial area under the concentration-time curve with a cut-off point at the tmax of the reference product [AUCp], peak plasma drug concentration [Cmax], the ratio Cmax/AUC0-∞, and mean residence time [MRT]). The point estimates of pharmacokinetic parameters (geometric means of the ratios test [T]/reference [R] and the 90% CIs for the ratios of geometric means [T]/[R]), estimated by parametric and nonparametric analysis, were used in the statistical analysis.
Results: The point estimates and the 90% CIs after parametric analysis of AUC0-∞ were 0.98 and (0.96–1.21), and after nonparametric analysis were 1.06 and (0.95–1.207), respectively. The two drug products were considered to be bioequivalent and with significant variability across subjects for the pharmacokinetic parameters AUC0–36, AUC0-∞, Cmax and MRT according to analysis of variance of log-transformed data.
Conclusions: The two studied formulations of metformin were found to be bioequivalent. They showed similar extents and rates of absorption and similar exposure. However, analysis of variance of logarithmically transformed data revealed significant variability among individuals in AUC0–36, AUC0-∞ and Cmax, making careful individualisation of the metformin dosage important.
KeywordsMetformin Pharmacokinetic Parameter Lactic Acidosis Mean Residence Time Reference Product
The study was funded by the Chemical Pharmaceutical Research Institute, NIHFI, Sofia Bulgaria. The authors have provided no information on conflicts of interest directly relevant to the content of this study.
- 1.Cusi K, DeFronzo R. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6(2): 89–131Google Scholar
- 3.Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group: United Kingdom prospective diabetes study (UKPDS) 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124 (1 pt 2): 136–45PubMedGoogle Scholar
- 8.Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general considerations. Available from URL: www.fda.gov/cder/guidance/5356fnl.doc [Accessed 2003 Mar]
- 14.Luft D, Schmulling R, Eggstein M. Lactic acidosis in biguanide-treated diabetes: a review of 330 cases. Diabetologia 1983; 24: 351–4Google Scholar